Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Pfizer | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Pfizer

Biopharma revenues were up 3% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer
1Q Revenues: $13.1 billion (+2%)
1Q Earnings: $3.9 billion (+9%)
Comments: Biopharma revenues were $9.2 billion in the quarter, up 3% driven by Eliquis (up 32% to $1.0 billion), Ibrance (up 21% to $1.1 billion), Prevnar 13/Prevenar 13 (+8% to $1.5 billion) and Xeljanz (+30% to $423 million). Upjohn revenues were $3.1 billion, down 1%, with growth in China, primarily from Lipitor, Norvasc and Celebrex, partially offset by 3% operational decline in developed markets excluding Japan, primarily driven by lower revenues for: Viagra (-22% to $145 million) and Upjohn’s authorized generic for Viagra in the U.S. resulting from increased generic competition, Lyrica (down 2% to $1.2 billion) due to lower volumes in the U.S., and anticipated generic competition in Europe, and Greenstone, Upjohn’s authorized generic subsidiary, primarily due to continued industry-wide pricing challenges in the U.S. Consumer Healthcare sales were $858 million, down 5%. At the start of the 2019 fiscal year, Pfizer reorganized its commercial operations into three businesses: Pfizer Biopharmaceuticals Group, which includes all of the previous Innovative Health business units (except Consumer Healthcare) as well as a new Hospital business unit includes Pfizer’s contract manufacturing operation, Pfizer CentreOne. Pfizer also incorporated its biosimilar portfolio into its Oncology and Inflammation & Immunology business units and certain legacy established products into the Internal Medicine business unit.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters